OBI-3424（Cat No.:I033772）is a prodrug selectively activated by aldo-keto reductase family 1 member C3 (AKR1C3), an enzyme overexpressed in certain cancers such as hepatocellular carcinoma, acute lymphoblastic leukemia, and prostate cancer. Upon activation, OBI-3424 releases a potent DNA-alkylating agent that induces double-strand breaks, leading to cancer cell death. Its tumor-selective activation minimizes damage to healthy tissues, offering a targeted chemotherapeutic strategy. Preclinical studies have shown strong antitumor activity and favorable tolerability. OBI-3424 is currently under clinical investigation as a precision oncology treatment for AKR1C3-overexpressing malignancies.